Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- cardiac
- Disease
- Medical
- Delivery
- Device
- Pharmaceuticals
- Enzymes
- Cancer
- Therapeutic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 368506
License Grant
Licensor, a nonprofit American academic medical center, grants to Licensee an exclusive, world-wide, royalty-bearing license, with the right to sublicense pursuant to this Agreement, under the Patents and Improvements, and a nonexclusive right under the Know-How to develop, make, have made, use, sell, import, offer to sell and commercialize Products within the Territory and within the Field.
License Property
US Patent granted June 2002, #6,407,211 – Chimeric natriuretic peptides
US Patent granted November 2004, #6,818,619 – Chimeric natriuretic peptides
CD-NP is a rationally-designed synthetic peptide developed to incorporate the optimal components of naturally occurring natriuretic peptides. CD-NP is a selective NPRB agonist that has shown potent renal enhancement and cardiac unloading properties in vivo. Importantly, however, CD-NP appears to do so with minimal hypotensive effects as compared with competitive products. In multiple preclinical studies, including a large animal model of congestive heart failure, CD-NP demonstrated potent therapeutic activity.
Field of Use
CD-NP may be useful in several cardiovascular and renal indications, and is initially being developed as a treatment for heart failure.
IPSCIO Record ID: 203275
License Grant
Licensor, a nonprofit American academic medical center, grants an exclusive, world-wide license, with the right to sublicense, under the Patents and Improvements, and a nonexclusive right under the Know-How to develop, make, have made, use, sell, import, offer to sell and commercialize Products within the Territory and within the Field.
License Property
The intellectual property and know-how relates to a novel synthetic natriuretic compound, named CU-NP, based on the ring structure of human CNP and both C- and N-termini of urodilatin, referred to as the invention.
CU-NP is a natriuretic peptide that consists of amino acid chains identical to those produced by the human body, specifically the ring structure of C-type natriuretic peptide, or CNP, and the N- and C-termini of Urodilatin, or URO, which exhibits cardiac unloading actions while minimizing the blood pressure lowering effects of CNP and augmenting the physiological effects of natriuresis.
Field of Use
The Field means all therapeutic indications.
CU-NP have shown it to
Increase the release of sodium by increasing elimination (via urine)
Increase glomerular filtration rate (a measure of kidney function) in a dose dependent manner
Decrease pressures in the heart
Regulate the fluid balance in the body without significantly reducing blood pressure
IPSCIO Record ID: 279319
License Grant
The Parties will undertake a Drug-Device testing program using Licensee’s Drug (including specific and necessary formulations of the Drug) in a Licensor Device to permit the parties’ evaluation of potential further testing and development of a Drug/Device combination therapy. Licensor will provide Mini-Med® Paradigm Insulin Pumps and Sertable® Infusion Sets as further specified in the Work Plan. Licensor shall retain ownership of the Pumps and Licensee shall return the Pumps to Licensor upon completion of the Clinical Study.
License Property
Product means any Drug, Device, or Drug/Device combination developed pursuant to the Agreement.
Drug means the hybrid natriuretic peptides (CD-NP) known as cenderitide as defined in US Patent Number(s) 6,407,211 owned or licensed or otherwise acquired by or assigned to Nile, which exist at the Effective Date.
Cenderitide, our lead product candidate, is a chimeric natriuretic peptide that we are developing for the treatment of heart failure.
6,407,211 – Chimeric natriuretic peptides
Licensee Patents focus on the use of hybrid natriuretic peptides, including but not limited to CD-NP, as defined.
Licensee Patents means the following Intellectual Property
6,818,619 – Chimeric natriuretic peptides
7,384,917 – Chimeric natriuretic peptides
Intellectual Property means all forms of intellectual property in any jurisdiction and under any law, whether now or hereafter existing, including (a) inventions, discoveries, patent applications, patents (including letters patent, industrial designs, and inventor’s certificates), design registrations, invention disclosures, and applications to register industrial designs, and any and all rights to any of the foregoing anywhere in the world, including any provisionals, substitutions, extensions, supplementary patent certificates, reissues, re-exams, renewals, divisions, continuations, continuations in part, continued prosecution applications, and other similar filings or notices provided for under the laws of the United States, or of any other country; (b) trade secrets and other confidential or non-public business information, including ideas, formulas, compositions, inventor’s notes, discoveries, improvements, concepts, know-how, manufacturing and production processes and techniques, testing information, research and development information, data resulting or derived from research activities, inventions, invention disclosures, unpatented blue prints, drawings, specifications designs, plans, proposals and technical data, business and marketing plans, market surveys, market know-how and customer lists and related information; (c) copyrights, whether or not registered, and any non-registered copyright to any writings and other copyrightable works of authorship, including source code, object code, documentation (whether or not released), and databases; (d) features of shape, configuration, pattern or ornament; and (e) registrations of, and applications to register, any of the foregoing with any governmental entity and any renewals or extensions thereof and all other rights to any of the foregoing.
Clinical Study means the Phase IIa feasibility study designed by Nile to be conducted hereunder as further set forth in this agreement.
Field of Use
Licensor will provide the equipment necessary for the Licensee to conduct its planned Phase I clinical trial to assess the pharmacokinetics and pharmacodynamics of cenderitide when delivered to heart failure patients through continuous subcutaneous infusion using Licensor’s diabetes pump technology.
IPSCIO Record ID: 7466
License Grant
The Licensor, government public health organization, hereby grants and Licensee accepts, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.
License Property
Development and commercialization of this technology will provide treatment and mitigation of the following cardiovascular diseases peripheral artery disease (PAD), intermittent claudication, coronary artery disease (CAD), dyslipidemia, angina pectoris, myocardial infarction, atherosclerosis, coronary plaque stabilization, carotid atherosclerosis, congestive heart failure, cerebral stroke, post-ischemic reperfusion and inflammation of the cardiovascular system. Development and commercialization of this technology will also provide treatment of cardiovascular related peri and post-surgical inflammation associated with transplants.
Field of Use
Fields of Use of the Licensed Property is for prevention, treatment and mitigation of the following cardiovascular diseases peripheral artery disease (PAD), intermittent claudication, coronary artery disease (CAD), dyslipidemia, angina pectoris, myocardial infarction, atherosclerosis, coronary plaque stabilization, carotid atherosclerosis, congestive heart failure, cerebral stroke, post-ischemic reperfusion, inflammation of the cardiovascular system and the treatment of cardiovascular related peri and post-surgical inflammation associated with transplants.
IPSCIO Record ID: 240469
License Grant
This amendments revises the intellectual property, royalties and identifies potential options to be exercised. This agreement is for enoximone property and processes.
License Property
Enoximone is a small organic molecule that exhibits highly selective inhibition of type-III phosphodiesterase, or PDE-III, an enzyme that is present in the heart and plays an important regulatory role in cardiac function.
The licensed property is Angiotensin-converting enzyme genetic variant screens; Transgenic model and treatment for heart disease; Transgenic Model for Heart Failure; Method for identifying adrenergic receptor antagonists having good tolerability; Diagnosis and treatment of myocardial failure; Method of treating heart failure; Inhibition of HDAC as a treatment for cardiac hypertrophy; and, Quantitative analysis of closely related protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry.
Field of Use
Licensee is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders.
IPSCIO Record ID: 204350
License Grant
Licensor grants to the United Kingdom Licensee a sole and exclusive license under the License Patents and Know-How and the trademark to develop, use, import, formulate, package, sell and offer for sale Products within the Field in the Territory.
License Property
The patents cover Recombinant Techniques for Production of Novel Natriuretic and Vasodilator Peptides; Physiologically Active HBNP, DNA Fragment Coding for the HBNP and Production Thereof; and Method for Producing a Peptide with a pl above 8 or above 5.
Trademark means the Natrecor(R) trademark. The Active Pharmaceutical Ingredient means Natrecor®. Natrecor® means nesiritide or B-type natriuretic peptide (BNP) the amino acid sequence.
Nesiritide (Natrecor) is the recombinant form of the 32 amino acid human B-type natriuretic peptide, which is normally produced by the ventricular myocardium. Nesiritide works to facilitate cardiovascular fluid homeostasis through counterregulation of the renin–angiotensin–aldosterone system, stimulating cyclic guanosine monophosphate, leading to smooth muscle cell relaxation. Neseritide was believed initially to be beneficial for acute decompensated congestive heart failure.
Field of Use
The Field means the development, use, distribution, importation, storage, marketing, sale and offer for sale of Product for any human pharmaceutical use other than as a diagnostic reagent.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
